GleamWall
中文EN

COCP Cocrystal Pharma, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1412486 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-17.2%
TTM EPS YoY18.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-219.1%
ROA-131.6%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets60.5%
Debt / equity0.00x
Current ratio1.72x
Interest coverage122.45x

Cash quality & payout

Operating cash flow / net income0.78x
Accruals ratio-28.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$5.05M$12.54M
SG&A expense$3.96M$5.34M
Operating income-$9.02M-$17.88M
Interest expense-$134,000-$537,000
Pretax income-$8.83M-$18.63M
Net income-$8.83M-$17.50M
EBITDA-$8.95M-$17.75M
EPS (basic)-0.78-1.72
EPS (diluted)-0.78-1.72
Weighted avg. shares (diluted)11.29M10.17M
Balance sheet
Cash & equivalents$7.03M$9.86M
Current assets$8.13M$11.58M
PP&E, net$93,000$153,000
Total assets$9.71M$13.46M
Current liabilities$2.21M$2.43M
Total liabilities$3.38M$3.93M
Shareholders' equity$6.33M$9.52M
Shares outstanding13.78M10.17M
Cash flow statement
Operating cash flow-$8.19M-$16.48M
Capital expenditure$12,000$8,000
Free cash flow-$8.20M-$16.49M
Investing cash flow-$12,000-$8,000
Financing cash flow$5.37M—
Depreciation & amortization$72,000$126,000
Stock-based compensation$270,000$643,000

Free plan shows the latest 2 periods; Pro shows all 16 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.